Who to call at Daiichi Sankyo Healthcare Co, and when
Fundz watches for the moments Daiichi Sankyo Healthcare Co starts buying, and tells you who to reach.
- An alert the day Daiichi Sankyo Healthcare Co raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Daiichi Sankyo Healthcare Co, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Daiichi Sankyo Healthcare Co. With Fundz connected, it knows.
Daiichi Sankyo and iDEL Therapeutics Forge Global Research Partnership for Cancer Drug Development.
Contract Type
partnership
TokyoBiotechnologyHealth CarePharmaceuticalDescription
Daiichi Sankyo and iDEL Therapeutics have entered a multi-year global research collaboration to develop a new multi-drug conjugate platform aimed at targeted delivery into solid tumor cells. This collaboration is expected to enhance Daiichi Sankyo's oncology product offerings and address significant drug delivery challenges.
Quick answer
Daiichi Sankyo and iDEL Therapeutics Forge Global Research Partnership for Cancer Drug Development. (November 10, 2026). Daiichi Sankyo Healthcare Co is based in Tokyo, Japan.
- What agreement did Daiichi Sankyo Healthcare Co announce on November 10, 2026?
- Daiichi Sankyo and iDEL Therapeutics have entered a multi-year global research collaboration to develop a new multi-drug conjugate platform aimed at targeted delivery into solid tumor cells. This collaboration is expected to enhance Daiichi Sankyo's oncology product offerings and address significant drug delivery challenges.
- What does Daiichi Sankyo Healthcare Co do?
- Daiichi Sankyo Healthcare Co specializes in consumer healthcare products, including OTC medicines, skincare, and nutritional items.
- Where is Daiichi Sankyo Healthcare Co based?
- Daiichi Sankyo Healthcare Co is based in Tokyo, Japan.
- Which similar companies announced agreements around the same time?
- Essential Pharma (November 9, 2026), AbbVie Inc. (November 3, 2026), Teva Pharmaceutical Industries Ltd (November 3, 2026) and Alexion (October 29, 2026) also announced agreements within 45 days of Daiichi Sankyo Healthcare Co.
Source: Fundz verified event record.
Other recent agreements in Pharmaceutical and Biotechnology
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- Essential Pharma and Nordmark establish partnership for UK availability of Norzyme® capsules for pancreatic insufficiency. (November 9, 2026)
- AbbVie partners with McLaren Racing in a multiyear collaboration to promote liver health awareness through Formula 1. (November 3, 2026)
- Teva and Samsung Bioepis Sign Agreement for U.S. Rights to Biosimilars Infliximab and Etanercept. (November 3, 2026)
- Wolves Foundation and Alexion extend partnership to support Wolves Disability FC and Wolves Wishes for three more years. (October 29, 2026)
- Merck Forms Partnership with NVIDIA, Microsoft, and Dawn Health to Enhance Support for Rare Tumor Patients (October 22, 2026)
- DARPA Awards Up to $10.7 Million Contract to RxMP Therapeutics for Development of RMP-402. (October 20, 2026)
Related People
Agreement Insights
What this usually meansDaiichi Sankyo Healthcare Co signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.